ReviewContemporary oncology (Poznan, Poland)2015
Two drugs are better than one. A short history of combined therapy of ovarian cancer.
Review in Contemporary oncology (Poznan, Poland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Oncogenic PI3Kα variants reveal graded conformational spectrum with mutation-specific cryptic pockets.Communications chemistry · 2026Article
- Oncogenic PI3Kα variants reveal graded conformational spectrum with mutation-specific cryptic pockets.bioRxiv : the preprint server for biology · 2025Article
- Treatment of ovarian cancer: From the past to the new era (Review).Oncology letters · 2025Review
- A Multi-Faceted Analysis ShowingInternational journal of molecular sciences · 2024Article
- A Comprehensive Review of Interventional Clinical Trials in Patients with Bone Metastases.OncoTargets and therapy · 2023Review
- A technical note on emerging combination approach involved in the onconanotherapeutics.Drug delivery · 2022Review
- Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma.Cancers · 2022Article
- Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges.Molecules (Basel, Switzerland) · 2022Review
- Metabolomics-Based Pharmacodynamic Analysis of Zhuang Yao Shuang Lu Tong Nao Granules in a Rat Model of Ischemic Cerebral Infarction.Analytical cellular pathology (Amsterdam) · 2022Article
- Therapeutic Implications of Caffeic Acid in Cancer and Neurological Diseases.Frontiers in oncology · 2022Review
- Potential Therapeutic Implications of Caffeic Acid in Cancer Signaling: Past, Present, and Future.Frontiers in pharmacology · 2022Review
- Editorial: Novel Combination Therapies for the Treatment of Solid Cancers.Frontiers in oncology · 2021Article
- Computationally predicting clinical drug combination efficacy with cancer cell line screens and independent drug action.Nature communications · 2020Article
- Pectasol-C Modified Citrus Pectin targets Galectin-3-induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids.Cancer medicine · 2019Article
- High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.International journal of molecular sciences · 2019Review
- Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN.Oncology reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined therapy of ovarian cancer has a long history. It has been applied for many years. The first drug which was commonly combined with other chemotherapeutics was cisplatin. It turned out to be effective given together with alkylating agents as well as with taxanes. Another drug which is often the basis of first-line therapy is doxorubicin. The use of traditional chemotherapy is often limited due to side effects. This is why new drugs, targeted specifically at cancer cells (e.g. monoclonal antibodies or epidermal growth factor receptor inhibitors), offer a welcome addition when used in combination with conventional anticancer agents. Drugs applied in combination should be synergistic or at least additive. To evaluate the type of interaction between drugs in a plausible sequence, isobolographic analysis is used. This method allows one to assess whether the two agents could make an efficient combination, which might improve the therapy of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.